TY - JOUR
T1 - Efficacy of stem cell secretome loaded in hyaluronate sponge for topical treatment of psoriasis
AU - Carrillo, Daniela
AU - Edwards, Natalie
AU - Arancibia-Altamirano, David
AU - Otárola, Fabiola
AU - Villarroel, Cynthia
AU - Prieto, Catalina P.
AU - Villamizar-Sarmiento, María Gabriela
AU - Sauma, Daniela
AU - Valenzuela, Fernando
AU - Lattus, José
AU - Oyarzun-Ampuero, Felipe
AU - Palma, Verónica
N1 - Publisher Copyright:
© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
PY - 2023/3
Y1 - 2023/3
N2 - Psoriasis vulgaris is an inflammatory disease characterized by distinctive skin lesions and dysregulated angiogenesis. Recent research uses stem cell secretion products (CM); a set of bioactive factors with therapeutic properties that regulate several cellular processes, including tissue repair and angiogenesis. The aim of this work was to evaluate the effect of CM of Wharton's gelatin MSC (hWJCM) in a treatment based on the bioactivation of a hyaluronic acid matrix (HA hWJCM) in a psoriasiform-like dermatitis (PD) mouse model. A preclinical study was conducted on PD mice. The effect of hWJCM, Clobetasol (Clob) gold standard, HA Ctrl, and HA hWJCM was tested topically evaluating severity of PD, mice weight as well as skin, liver, and spleen appearance. Treatment with either hWJCM, HA Ctrl or HA hWJCM, resulted in significant improvement of the PD phenotype. Moreover, treatment with HA hWJCM reduced the Psoriasis Area Severity Index (PASI), aberrant angiogenesis, and discomfort associated with the disease, leading to total recovery of body weight. We suggest that the topical application of HA hWJCM can be an effective noninvasive therapeutic solution for psoriasis, in addition to other skin diseases, laying the groundwork for future studies in human patients.
AB - Psoriasis vulgaris is an inflammatory disease characterized by distinctive skin lesions and dysregulated angiogenesis. Recent research uses stem cell secretion products (CM); a set of bioactive factors with therapeutic properties that regulate several cellular processes, including tissue repair and angiogenesis. The aim of this work was to evaluate the effect of CM of Wharton's gelatin MSC (hWJCM) in a treatment based on the bioactivation of a hyaluronic acid matrix (HA hWJCM) in a psoriasiform-like dermatitis (PD) mouse model. A preclinical study was conducted on PD mice. The effect of hWJCM, Clobetasol (Clob) gold standard, HA Ctrl, and HA hWJCM was tested topically evaluating severity of PD, mice weight as well as skin, liver, and spleen appearance. Treatment with either hWJCM, HA Ctrl or HA hWJCM, resulted in significant improvement of the PD phenotype. Moreover, treatment with HA hWJCM reduced the Psoriasis Area Severity Index (PASI), aberrant angiogenesis, and discomfort associated with the disease, leading to total recovery of body weight. We suggest that the topical application of HA hWJCM can be an effective noninvasive therapeutic solution for psoriasis, in addition to other skin diseases, laying the groundwork for future studies in human patients.
KW - Wharton's gelatin mesenchymal stem cells conditioned media
KW - freeze dried bioactive sponge
KW - hyaluronic acid
KW - psoriasis
KW - secretoma
KW - tortuous blood vessels
KW - γδ lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85148590060&partnerID=8YFLogxK
U2 - 10.1002/btm2.10443
DO - 10.1002/btm2.10443
M3 - Article
AN - SCOPUS:85148590060
SN - 2380-6761
VL - 8
JO - Bioengineering and Translational Medicine
JF - Bioengineering and Translational Medicine
IS - 2
M1 - e10443
ER -
